Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer

Inclusion Criteria:

• Patients must have newly diagnosed stage I-IV, persistent or recurrent (includingunstaged) uterine carcinosarcoma (malignant mixed mullerian tumor-MMMT or withovarian, fallopian tube or peritoneal carcinosarcoma and an enrollment date prior to 10/21/2013; pathology confirmed by site/institutional pathologist prior to enrollment)and be chemotherapy naïve as directed against their carcinosarcoma; unstaged patients (patients who have not had hysterectomy or ovarian surgery) are eligible and should beincluded as "unstaged" if the only histologic (pathology) documentation of the diseaseis a biopsy or curettage of the uterus; if these patients have documented metastaticdisease, it should be assigned the appropriate stage (III/IV)
• Patients may have received prior adjuvant external beam radiation therapy and/orvaginal brachytherapy; patients should be at least 4 weeks from the completion ofexternal beam radiotherapy prior to beginning protocol chemotherapy; patients do notneed to be delayed if receiving vaginal brachytherapy only
• Gynecologic Oncology Group (GOG) performance status 0, 1, or 2
• Patients must have recovered from the effects of recent surgery, radiotherapy, orother therapy
• Patients must be free of active infection requiring antibiotics
• Any hormonal therapy directed at the malignant tumor must be discontinued at least oneweek prior to beginning protocol chemotherapy; continuation of hormone replacementtherapy is permitted
• Platelet count greater than or equal to 100,000/mcL
• Absolute neutrophil count (ANC) greater than or equal to 1,500/mcL equivalent toCommon Terminology Criteria for Adverse Events (CTCAE) version (v)3.0 grade 1
• Creatinine less than or equal to 1.5 times upper limit of normal (ULN), CTCAE v3.0grade 1
• Bilirubin less than or equal to 1.5 times ULN (CTCAE v3.0 grade 1)
• Serum glutamic oxaloacetic transaminase (SGOT) less than or equal to 2.5 times ULN (CTCAE v3.0 grade 1)
• Alkaline phosphatase less than or equal to 2.5 times ULN (CTCAE v3.0 grade 1)
• Serum albumin should be equal to or greater than 3 g/dL
• Neuropathy (sensory and motor) less than or equal to CTCAE v3.0 grade 1
• Patients must have signed an approved informed consent and authorization permittingrelease of personal health information
• Patients of childbearing potential must have a negative serum pregnancy test prior tostudy entry and be practicing an effective form of contraception
• Patients may have measurable disease or non-measurable disease; measurable disease isdefined as at least one lesion that can be accurately measured in at least onedimension (longest dimension to be recorded); each lesion must be >= 20 mm whenmeasured by conventional techniques, including palpation, plain x-ray, computedtomography (CT), and magnetic resonance imaging (MRI), or >= 10 mm when measured byspiral CT; measurable disease patients must have at least one "target lesion" to beused to assess progression on this protocol as defined by Response Evaluation CriteriaIn Solid Tumors (RECIST); tumors within a previously irradiated field will bedesignated as "non-target" lesions unless progression is documented or a biopsy isobtained to confirm persistence at least 90 days following completion of radiationtherapy

Exclusion Criteria:

• Patients who have received prior cytotoxic chemotherapy for management of uterine orovarian carcinosarcoma
• Patients with a history of other invasive malignancies or with a concomitant invasivemalignancy, with the exception of non-melanoma skin cancer, if there is any evidenceof other malignancy being present within the last five years; patients are alsoineligible if their previous cancer treatment contraindicates this protocol therapy
• Patients for whom radiotherapy is planned after or during chemotherapy prior toprogression of cancer
• Patients with known hypersensitivity to Escherichia (E.) coli-derived drugpreparations (pegfilgrastim and filgrastim [G-CSF])
• Patients with a known hypersensitivity to mesna or other thiol compounds
• For enrollment prior to 10/21/2013, patients who are not biopsy proven to havecarcinosarcoma of the uterus, fallopian tube, peritoneum or ovary; for enrollmentafter 10/21/2013, patients who are not biopsy proven to have carcinosarcoma of theuterus